124 related articles for article (PubMed ID: 3011442)
1. Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemia.
Hock CE; Brezinski ME; Lefer AM
Eur J Pharmacol; 1986 Mar; 122(2):213-9. PubMed ID: 3011442
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotective actions of specific thromboxane receptor antagonist in acute myocardial ischemia.
Brezinski ME; Yanagisawa A; Lefer AM
J Cardiovasc Pharmacol; 1987 Jan; 9(1):65-71. PubMed ID: 2434797
[TBL] [Abstract][Full Text] [Related]
3. Anti-ischemic actions of a new thromboxane receptor antagonist during acute myocardial ischemia in cats.
Brezinski ME; Yanagisawa A; Darius H; Lefer AM
Am Heart J; 1985 Dec; 110(6):1161-7. PubMed ID: 3000159
[TBL] [Abstract][Full Text] [Related]
4. Beneficial actions of the thromboxane receptor antagonist, AH-23,848, in acute myocardial ischemia.
Brezinski ME; Osborne JA; Yanagisawa A; Lefer AM
Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):703-9. PubMed ID: 2966270
[TBL] [Abstract][Full Text] [Related]
5. Protective actions of a thromboxane receptor antagonist, SQ 29548 on the ischemic myocardium: morphologic and hemodynamic effects.
Singh J; Seth SD; Manchanda SC; Seth S
Prostaglandins Leukot Essent Fatty Acids; 1997 Feb; 56(2):105-10. PubMed ID: 9051718
[TBL] [Abstract][Full Text] [Related]
6. CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion.
Hock CE; Lefer AM
Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):285-94. PubMed ID: 3755540
[TBL] [Abstract][Full Text] [Related]
7. The effect of the thromboxane A2 receptor antagonist SQ 29,548 on the severity of pacing-induced ischemia.
Grover GJ; Schumacher WA
Basic Res Cardiol; 1989; 84(1):103-10. PubMed ID: 2522297
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of thromboxane actions in the isolated perfused rat heart.
Stahl GL; Darius H; Lefer AM
Life Sci; 1986 Jun; 38(22):2037-41. PubMed ID: 2940431
[TBL] [Abstract][Full Text] [Related]
9. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist.
Nichols WW; Mehta J; Wargovich TJ; Franzini D; Lawson D
Angiology; 1989 Mar; 40(3):209-21. PubMed ID: 2537051
[TBL] [Abstract][Full Text] [Related]
10. Role of thromboxane A2 in the control of myocardial O2 supply/consumption balance and severity of ischemia during pacing-induced ischemia.
Grover GJ; Parham CS
Circ Res; 1989 Mar; 64(3):575-82. PubMed ID: 2917381
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotective actions of the specific thromboxane receptor antagonist (+)-S145Na following coronary occlusion and reperfusion in the rat.
Tsao PS; Lefer AM
Res Commun Chem Pathol Pharmacol; 1990 Nov; 70(2):205-11. PubMed ID: 2148980
[TBL] [Abstract][Full Text] [Related]
12. Additive beneficial effects of two inhibitors of vasoconstrictor mediators in acute myocardial ischemia.
Bitterman H; Lefer DJ; Lefer AM
Proc Soc Exp Biol Med; 1987 Jul; 185(3):262-6. PubMed ID: 3037554
[TBL] [Abstract][Full Text] [Related]
13. Effect of the thromboxane receptor antagonist SQ 29,548 on myocardial infarct size in dogs.
Grover GJ; Schumacher WA
J Cardiovasc Pharmacol; 1988 Jan; 11(1):29-35. PubMed ID: 2450253
[TBL] [Abstract][Full Text] [Related]
14. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of combined thromboxane and leukotriene receptor antagonism in hemorrhagic shock.
Patel JP; Beck LD; Briglia FA; Hock CE
Crit Care Med; 1995 Feb; 23(2):231-7. PubMed ID: 7867347
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute myocardial ischaemia with a selective antagonist of thromboxane receptors (BM 13.177).
Schrör K; Thiemermann C
Br J Pharmacol; 1986 Apr; 87(4):631-7. PubMed ID: 3011166
[TBL] [Abstract][Full Text] [Related]
17. Serotonin S2 and thromboxane A2-prostaglandin H2 receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries.
Ashton JH; Golino P; McNatt JM; Buja LM; Willerson JT
J Am Coll Cardiol; 1989 Mar; 13(3):755-63. PubMed ID: 2521875
[TBL] [Abstract][Full Text] [Related]
18. Effect of propranolol on ischemic myocardial damage and left ventricular hypertrophy following permanent coronary artery occlusion or occlusion followed by reperfusion.
Smith EF; Egan JW; Griswold DE
Pharmacology; 1989; 38(5):298-309. PubMed ID: 2527373
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective actions of thromboxane receptor antagonism in ischemic atherosclerotic rabbits.
Osborne JA; Lefer AM
Am J Physiol; 1988 Aug; 255(2 Pt 2):H318-24. PubMed ID: 2970233
[TBL] [Abstract][Full Text] [Related]
20. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
Smith EF; Griswold DE; Egan JW; Hillegass LM; DiMartino MJ
J Cardiovasc Pharmacol; 1989 May; 13(5):715-22. PubMed ID: 2472519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
